Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors

NCT ID: NCT02268435

Last Updated: 2015-08-04

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-31
• Study Completion Date: 2016-11-30

Brief Summary

The objective of this study is to determine the recommended dose of combination of dovitinib and imatinib in phase I study.

Detailed Description

combination of dovitinib and imatinib could lead to additive or synergistic effect in patients who had failure of standard TKI therapies including imatinib, sunitinib, and/or regorafenib. In this phase I-II study of dovitinib plus imatinib, we aim to determine a recommended dose of dovitinib plus imatinib and to evaluate the safety and activity of the combination at the recommended dose as a 3rd or more line of treatment in metastatic or unresectable GIST.

Conditions

Gastrointestinal Stromal Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dovitinib plus Imatinib

Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule

Group Type: EXPERIMENTAL

dovitinib plus imatinib

Intervention Type: DRUG

Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule

Interventions

dovitinib plus imatinib

Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age 19 years or older

2. Histologically confirmed metastatic or unresectable GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene

3. Disease control (response or stabilization for at least 6 months with first-line imatinib and failure of prior treatments for GIST, including at least both imatinib and sunitinib and/or regorafenib. However, patients with imatinib rechallenge will not be accrued.

4. ECOG performance status of 0~2

5. Resolution of all toxic effects of prior treatments to grade 0 or 1

6. At least one evaluable or measurable lesion for phase I study

7. Adequate bone marrow, hepatic, renal, and other organ functions

• Neutrophil > 1,500/mm3
• Platelet > 75,000/mm3
• Hemoglobin > 8.0 g/dL
• Total bilirubin < 1.5 x upper limit of normal
• AST/ALT < 2.5 x ULN with no exceptions
• Creatinine < 1.5 x ULN

8. Life expectancy > 12 weeks

9. Women with reproductive potential must have a negative serum or urine pregnancy test; and men and women of reproductive potential must practice an effective method of avoiding pregnancy while receiving study drug.

10. Washout period of previous TKIs or chemotherapy for more than 4 times the half life.

11. No prior use of dovitinib or other inhibitors of FGFR except regorafenib

12. Provision of a signed written informed consent

Exclusion Criteria

1. Women of child-bearing potential who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial in both sexes.

2. Clinically significant cardiac disease or impaired cardiac function or clinically significant cardiac diseases, including any one of the following:

• LVEF < 45%
• Complete left bundle branch block
• Obligate use of a cardiac pacemaker
• Congenital long QT syndrome
• History or presence of ventricular tachyarrhythmia
• Presence of unstable atrial fibrillation .
• Clinically significant resting bradycardia
• Uncontrolled hypertension
• QTc > 480 msec on screening ECG
• Right bundle branch block + left anterior hemiblock
• Angina pectoris ≤ 3 months prior to starting study drug
• Acute Myocardial Infarction ≤ 3 months prior to starting study drug
• Other clinically significant heart disease

3. Uncontrolled infection

4. Subjects who did not tolerate previous imatinib treatment.

5. Diabetes mellitus with signs of clinically significant peripheral vascular disease

6. Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring two or more interventions/month 7. Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis, adrenal or thyroid glands

8. Prior acute or chronic pancreatitis of any etiology 9. Malabsorption syndrome or uncontrolled gastrointestinal toxicities with toxicity greater than NCI CTCAE grade 2 10. Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for this study 11. Treatment with any of the medications that have a potential risk of prolonging the QT interval or inducing Torsades de Points and the treatment cannot be discontinued or switched to a different medication prior to starting study drug 12. Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, rifampin, phenytoin and quinidine 2 weeks prior baseline 13. Major surgery ≤ 28 days prior to starting study drug or who have not recovered from side effects of such therapy 14. Known diagnosis of HIV infection 15. History of another primary malignancy that is currently clinically significant or currently requires active intervention 16. Patients with brain metastases as assessed by radiologic imaging due to symptoms clinically suspected of brain metastases 17. Alcohol or substance abuse disorder

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Asan Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Yoon-Koo Kang

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Yoon-Koo Kang, PhD

Role: PRINCIPAL_INVESTIGATOR

Asan Medical Center

Other Identifiers

AMC1401

Identifier Type: -

Identifier Source: org_study_id